Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Holdings Raised by Mackenzie Financial Corp

Mackenzie Financial Corp boosted its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 234.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,310 shares of the company's stock after buying an additional 78,070 shares during the quarter. Mackenzie Financial Corp owned 0.16% of Amylyx Pharmaceuticals worth $421,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. American Century Companies Inc. raised its stake in shares of Amylyx Pharmaceuticals by 181.8% in the 4th quarter. American Century Companies Inc. now owns 59,310 shares of the company's stock valued at $224,000 after purchasing an additional 38,261 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $205,000. Wellington Management Group LLP bought a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $793,000. Bank of America Corp DE grew its position in shares of Amylyx Pharmaceuticals by 165.9% during the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock valued at $9,171,000 after buying an additional 1,513,748 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $56,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Insider Buying and Selling

In other news, insider Camille L. Bedrosian sold 12,425 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $43,114.75. Following the completion of the transaction, the insider now owns 194,375 shares in the company, valued at approximately $674,481.25. This trade represents a 6.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of the stock in a transaction dated Thursday, March 20th. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $37,000.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $37,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 44,811 shares of company stock valued at $155,494 over the last quarter. Corporate insiders own 11.70% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AMLX. Mizuho boosted their price objective on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an "outperform" rating in a research report on Wednesday, May 14th. Leerink Partners raised shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $4.00 to $10.00 in a research report on Wednesday, May 7th. HC Wainwright boosted their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Finally, TD Cowen started coverage on shares of Amylyx Pharmaceuticals in a research report on Friday, May 30th. They issued a "buy" rating for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $9.83.

Amylyx Pharmaceuticals Stock Up 5.5%

NASDAQ AMLX traded up $0.28 on Friday, hitting $5.33. The stock had a trading volume of 757,278 shares, compared to its average volume of 1,204,596. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $7.27. The stock has a market cap of $475.12 million, a price-to-earnings ratio of -1.40 and a beta of -0.59. The company's 50-day moving average is $4.58 and its two-hundred day moving average is $4.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.03. On average, sell-side analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.